Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis

Unknown 40 enrolled Xi'an Jiaotong University

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this clinical trial is to determine the effect and security of low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis.

Timeline

Start: 2009-09
Primary completion: 2012-12
Completion: 2012-12

Publications

Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mycophenolate Mofetil	Small molecule	0.75 g	—
Subject	Prednisone	Other / unclassified	1 mg/kg	—
Subject	Prednisone	Other / unclassified	10 mg	—
Subject	Tacrolimus	Small molecule	0.2 mg/kg	—

Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis

Summary

Timeline

Publications

Drugs

Indications